Jacek Fijuth

Jacek Fijuth

Auto-generated profile, based on publicly available information

Jacek Fijuth

Department of Radiation Oncology, Medical University of Lodz, Lodz, Poland

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2011 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
MRMaciej Rupinski
Maciej Rupinski
EZEdyta Zagorowicz
Edyta Zagorowicz
JRJaroslaw Regula
Jaroslaw Regula
JFJacek Fijuth
Jacek Fijuth
EKEwa Kraszewska
Ewa Kraszewska
EBEugeniusz Butruk
Eugeniusz Butruk
Because most esophageal cancers are diagnosed at an advanced stage, a majority of patients require palliative dysphagia treatment. Dysphagia severity and the need for repeated re-canalization procedures significantly affect patients' quality of life (QoL). The aim of this study was to establish whether combining argon plasma coagulation (APC) of the neoplastic esophageal tissue with another re-canalization method results in a longer dysphagia-free period compared with APC alone. We conducted a randomized trial in 93 patients with malignant dysphagia. Patients were followed until death. We compared three regimens of esophageal re-canalization; APC combined with high dose rate (HDR) brachytherapy, APC combined with photodynamic therapy (PDT), and APC alone. The primary outcome measure was the dysphagia-free period following randomization. Secondary measures were survival, QoL, treatment-associated complications, and treatment tolerance. A per-protocol analysis was carried out. The time to first dysphagia recurrence was significantly different between each combination treatment group and the control group (overall test: P=0.006; HDR vs. control, log-rank P=0.002, PDT vs. control, log-rank P=0.036), but not different between the combination groups (HDR vs. PDT, log-rank P=0.36). The median time to first dysphagia recurrence was 88, 59, and 35 days in the HDR, PDT, and control groups, respectively. There was no difference in overall survival between the study groups (P=0.27). No deaths, perforations, hemorrhages, or fistula formations were attributed to treatment. The only major complication was fever, occurring in three PDT patients. Minor complications were observed significantly more often in the combination treatment groups and included pain in both groups, transient dysphagia worsening, and skin sensitivity in the PDT group. The QoL 30 days after treatment in the HDR group was significantly better than in the other groups. In patients with inoperable esophageal cancer, palliative combination treatment of dysphagia with APC and HDR or PDT was significantly more efficient than APC alone, and was safe and well tolerated. APC combined with HDR resulted in fewer complications and better QoL than APC with PDT or APC alone (CONSORT 1b).

1 January 2005 in Acta Oncologica
Verified
Journal Article
Closed access
LKLucyna Kepka
Lucyna Kepka
ECEwa Cieslak
Ewa Cieslak
KBKrzysztof Bujko
Krzysztof Bujko
JFJacek Fijuth
Jacek Fijuth
MWMarek Wierzchowski
Marek Wierzchowski
We evaluated the overall survival with respect to prognostic factors in patients with brain metastases (BM) from lung cancer in order to assess the RTOG RPA (Recursive Partitioning Analysis) classification value and to perform intra-classes analyses including pretreatment and treatment-related variables. Between 1986 and 1997, 322 consecutive patients with BM from lung cancer were treated with whole-brain radiotherapy. Patients' distribution according to the RTOG RPA classes was: Class 1--13%, Class 2--67% and Class 3--20%. Prognostic value of the following variables was tested: RTOG RPA classes, performance status, age, extracranial metastases, control of the primary tumour, gender, histology, number of BM and interval from diagnosis to the development of BM. Intra-classes analyses were performed including radiation dose and surgery of BM. Median survival was 4.0 months. Median survival for RTOG RPA classes 1, 2 and 3 were 5.2, 4.0 and 2.5 months, respectively (p = 0.003). Extracranial metastases, performance status, control of the primary and RTOG RPA classes were prognostic for survival. Within class 2 higher radiation dose, female, no extracranial metastases and surgery of BM were related to the improved survival. RTOG RPA classes maintain their prognostic significance for patients with BM from lung cancer not participating in clinical trials.

1 July 2011 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
PDF file
VGVincent Gregoire
Vincent Gregoire
Marc HamoirMarc Hamoir
Marc Hamoir
CCChanghu Chen
Changhu Chen
MKMadeleine Kane
Madeleine Kane
AKAndrzej Kawecki
Andrzej Kawecki
DRDavid Raben
David Raben

1 January 1992 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
PDF file
JFJacek Fijuth
Jacek Fijuth
JMJean-Jacques Mazeron
Jean-Jacques Mazeron
CPCécile Le Péchoux
Cécile Le Péchoux
PPPascal Piedbois
Pascal Piedbois
MMMichel Martin
Michel Martin
JBJean-Paul Le Bourgeois
Jean-Paul Le Bourgeois

1 July 1994 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
BCB Chauvet
B Chauvet
CFC Félix-Faure
C Félix-Faure
NLN Lupsascka
N Lupsascka
JFJ Fijuth
J Fijuth
YBY Brewer
Y Brewer
FRF Reboul
F Reboul
PURPOSE: To assess the prognostic significance of serum prostate-specific antigen (PSA) in the monitoring of patients with localized prostate cancer treated with primary radiation therapy, we analyzed the data from 179 patients treated at our institution between 1987 and 1990. PATIENTS AND METHODS: One hundred seventy-nine previously untreated patients received radiation at 69 Gy to the prostate with curative intent for prostate adenocarcinoma. The median follow-up duration is now 41 months. PSA levels were measured before radiotherapy and then evaluated periodically. RESULTS: Baseline levels were greater than 4 ng/mL in 83% of cases and were significantly correlated with clinical tumor stage (P = .002). Six months after completion of therapy, PSA values had returned to normal in 53% of the patients with initially elevated values. At the time of analysis, 32 patients have relapsed, including three of 30 patients (10%) with normal initial and 6-month values, five of 79 patients (6%) with initially elevated but normal 6-month values, and 24 of 69 patients (35%) with persistently elevated PSA levels at 6 months. Actuarial 4-year relapse-free survival was significantly correlated with initial and 6-month PSA values (84% in patients with normal 6-month values v 60% in patients with persistently elevated levels). Furthermore, when the relative decline between initial and 6-month PSA values exceeded 50%, the crude rate of recurrence was 14% as opposed to 34% when it failed to exceed 50%. The 4-year relapse-free survival rates were 77% and 59%, respectively (P = .008). By multivariate analysis restricted to the patients with elevated baseline PSA levels, the rate of decline of PSA values reached the highest prognostic significance (P < .0001). Age at diagnosis, clinical tumor stage, and Gleason score only reached statistical significance in univariate analysis. CONCLUSION: PSA values are of major prognostic significance in assessing the 4-year results of radical radiation therapy for localized prostate cancer. The rate of decline of PSA values is the strongest predictor of outcome and might help to identify a subset of patients with poorer prognosis who may benefit from early hormonal therapy.

1 January 2016 in Journal of Contemporary Brachytherapy
Verified
Journal Article
Open access
ŁKŁukasz Kuncman
Łukasz Kuncman
SKSławomir Kozłowski
Sławomir Kozłowski
APAndrzej Pietraszek
Andrzej Pietraszek
MPMalwina Pietrzykowska-Kuncman
Malwina Pietrzykowska-Kuncman
JDJustyna Danielska
Justyna Danielska
JFJacek Fijuth
Jacek Fijuth
Purpose : Brachytherapy (BT), due to rapid dose fall off and minor set-up errors, should be superior to external beam radiotherapy (EBRT) for treatment of lesions in difficult locations like nose and earlobe. Evidences in this field are scarce. We describe computed tomography (CT) based surface...